title: Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.
abstract: OBJECTIVE
  To evaluate outcomes of ablative allogeneic hematopoietic cell transplantation (HCT) in older patients with hematologic malignancies.
  
  
  METHODS
  We treated 52 patients from 1979 to 2002 with a median age of 62.8 years (range, 60.1 to 67.8 years) using ablative preparative regimens followed by allogeneic HCT from sibling donors. Diagnoses included myelodysplastic syndrome (MDS; n = 35), chronic myeloid leukemia (CML; n = 8), acute myeloid leukemia (AML; n = 6), and other (n = 3). Conditioning regimens included cyclophosphamide (CY) and busulfan (BU) (67%), total-body irradiation and CY (21%), BU-fludarabine (10%), and CY (2%).
  
  
  RESULTS
  Eighteen (35%) of 52 patients are alive at a median of 4.6 years (range, 0.8 to 9.1 years) after transplantation. Median overall survival (OS) and progression-free survival were 300 and 218 days, respectively. Three-year OS and relapse rates are estimated to be 34% and 24%, respectively. Nonrelapse mortality (NRM) rates at 100 days and 3 years are estimated to be 27% and 43%, respectively. Grade 3 to 4 acute graft-versus-host disease (GVHD) occurred in 20% of patients, and chronic extensive GVHD was described in 53% of patients. Fourteen (40%) of 35 patients with MDS are alive at a median of 2.8 years (range, 0.8 to 8.2 years). Four of six patients with CML in chronic or accelerated phase are alive at a median of 6.9 years (range, 4.1 to 9.1 years) after transplantation. None of the patients with AML, CML in blast crisis, or other diagnoses have survived. Patients who underwent transplantation after 1993 had improved survival.
  
  
  CONCLUSIONS
  These data suggest that allogeneic HCT is feasible in selected patients > or = 60 years of age, although novel methods to reduce NRM while maintaining efficacy are needed.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, D3-100, Seattle, WA 98109, USA. hwallen@u.washington.edu
authors.forename: Herschel
authors.initials: H
authors.lastname: Wallen
authors.forename: Theodore A
authors.initials: TA
authors.lastname: Gooley
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
authors.forename: John M
authors.initials: JM
authors.lastname: Pagel
authors.forename: Oliver W
authors.initials: OW
authors.lastname: Press
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: Rainer
authors.initials: R
authors.lastname: Storb
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000367:Age Factors; D000368:Aged; D016001:Confidence Intervals; D005260:Female; D006085:Graft Survival; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011336:Probability; D011379:Prognosis; D016016:Proportional Hazards Models; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome